发明名称 MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE
摘要 The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
申请公布号 US2016169911(A1) 申请公布日期 2016.06.16
申请号 US201615054255 申请日期 2016.02.26
申请人 Roche Diagnostics Operations, Inc. 发明人 Block Dirk;Brunner Hanspeter;Dieterle Thomas;Wienhues-Thelen Ursula-Henrike;Zaugg Christian;Ziegler Andre
分类号 G01N33/68;G01N33/62 主分类号 G01N33/68
代理机构 代理人
主权项 1. A method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin comprising: (a) measuring a level of the biomarker GDF-15 in a sample from the patient, and (b) comparing the level of GDF-15 to reference level.
地址 Indianapolis IN US